Team Grant - Emerging: Novel Alternatives to Antibiotics
CIHR and CIHR's Institute of Infection and Immunity (III) is pleased to announce the results of the "Team Grant - Emerging: Novel Alternatives to Antibiotics" competition.The specific objectives of the funding opportunity are to:
- To promote collaboration between researchers working immunology and microbiology to combine their expertise in addressing research questions related to the theme of novel alternatives to antibiotics;
- To promote collaboration between researchers working in the agriculture sector, on antibiotic resistance and alternatives to antibiotics in food animals, with those researchers working in a clinical environment;
- To create links between the public and private sector through the promotion of collaborations between the health, agriculture and industry sectors;
- To encourage the formation of interdisciplinary, multi-sector teams likely to provide novel alternatives to traditional antibiotics with practical applications in both agriculture and health;
- To foster cross-theme research with an emphasis on a multidisciplinary approach;
- To create a team environment that favours the development of excellent and innovative research projects that will advance our understanding in the area of alternatives to antibiotics;
- To train and establish new investigators capable of undertaking research in the area of alternatives to antibiotics.
A total of 27 teams were invited to submit a full application. Applications were reviewed by the Novel Alternatives to Antibiotics (NAA) Peer Review Committee, resulting in the approval of eight (8) applications. (Success rate of 30%)
| Name(s)/ Institution Paid/ Title |
Partner | Total funding | Term |
|---|---|---|---|
| DAVIDSON, Alan R GUTTMAN, David S MCGAVIN, Martin J University of Toronto Genetically Engineered Phage Tail-Like Bacteriocins as an Alternative to Antibiotics |
CIHR Institute of Infection and Immunity | $1,361,525 | |
| DENNIS, Jonathan J University of Alberta Bacteriophage Therapy Aerosol Delivery and Target Cell Interaction |
CIHR Institute of Infection and Immunity | $1,240,146 | 5 yr(s) |
| HOURY, Walid A University of Toronto Towards the Development of a Novel Class of Antibiotics: Activators of Self-Compartmentalizing Proteases |
CIHR Institute of Infection and Immunity | $1,461,000 | 5 yr(s) |
| MOINEAU, Sylvain Université Laval Phage therapy for antibiotic-resistant Streptococcus pneumoniae infection |
CIHR Institute of Infection and Immunity | $1,500,000 | 5 yr(s) |
| SAD, Subash University of Ottawa Development of novel lipid modulators of innate immunity |
CIHR Institute of Infection and Immunity | $1,468,250 | 5 yr(s) |
| VOGEL, Hans (Harm) J. University of Calgary Enhancing innate immunity, antibiotic activity and anti-endotoxin activity with mammalian antimicrobial peptides and proteins: studies of infected mouse models |
CIHR Institute of Infection and Immunity | $ 1,497,500 | 5 yr(s) |
| WEAVER, Donald F IWK Health Centre (Halifax) Lipid Membrane Disruptors as adjuncts to antibiotic therapy |
CIHR Institute of Infection and Immunity | $ 816,000 | 3 yr(s) |
| WRIGHT, Gerard D McMaster University Antibiotic Adjuvants: Overcoming multi-drug Resistance in Gram |
CIHR Institute of Infection and Immunity | $ 1,393,750 | 5 yr(s) |